Aratana Therapeutics, Inc. (Nasdaq: PETX) is a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats. Our mission is to successfully develop and deliver best-in-class therapeutics, provide comprehensive service to veterinarians and serve as a collaborator of choice for human and animal health companies. We believe our therapeutics are highly differentiated, resolve recognizable needs in compelling markets and have therapeutic profiles superior to the standard of care. Our FDA-approved and commercially available therapeutics include: - A prostaglandin receptor antagonist that specifically targets the EP4 receptor to target osteoarthritis pain and inflammation in dogs - A selective ghrelin receptor agonist that mimics ghrelin, the naturally-occurring “hunger hormone,” to stimulate appetite in dogs - A long-acting, local anesthetic that provides up to 72 hours post-operative pain relief following certain surgeries in dogs and cats